Precision Medicine in the country is considered to be at an early adoption stage. A diverse country like India, with over 4,000 population groups, and a significant percentage of consanguineous marriages presents a high-risk and prevalence of inherited genetic disorders that require attention for early diagnosis, right treatment, and management. India has a heavy burden of inherited diseases driven by the unique genetic characteristics in the population.

Transformative Years of BIOSIMILARS
2025 marks 25 years since India first ventured into the biosimilar space. Over the past quarter century, the country has consistently solidified its position as a global leader in biosimilar  approvals, with 135 approvals till January 2025. Initially focused on simpler biologics, the field now includes developing and approving complex monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), a diversified therapeutic focus, and a growing number of innovative players entering the field. As the industry celebrates this silver jubilee, we reflect on the journey that has 
not only transformed India's biotechnology sector but has also played a pivotal role in making life saving treatments more accessible and affordable worldwide.

RIPPLE EFFECT of Cancer Drug Duty Cuts 
To ease the financial strain on patients, the Union Budget 2025-26 has removed Basic
Customs Duty (BCD) on 36 life-saving drugs used for cancer, rare diseases, and  chronic conditions. This move is expected to make essential treatments more affordable by lowering overall costs. However, the real question remains: will this truly reduce the financial burden on patients? As prices decrease, what effects will this have on pharmaceutical companies, particularly in terms of sales and competition? Most importantly, how will local players adapt to these changes?

10 Women ‘Power Players’ of Bio Research & Policy
As revealed in Finance Minister Nirmala Sitharaman's Economic Survey 2024-
25, for the first time in seven years, India’s female labour force participation
rate (FLFPR) has seen a significant rise, jumping from 23.3 per cent in 2017-18 to 41.7 per cent in 2023-24. The Economic Survey underscores how womenled businesses thrive under government support. As of October 31, 2024, over 73,151 startups with at least one woman director have been recognised under the Startup India Initiative, nearly half of all registered startups in India. Additionally, Union Budget 2025-26 has listed new initiatives to support women
entrepreneurs across various sectors within the industry. While the number of
women entrepreneurs in the country has been increasing over the years, there has not been much change at the women leadership level in both the public and private sectors. There are very few women leaders who have the opportunity to take charge of an entire academic institute or a government posting, thereby contributing to the growth of our country.

How India is Pulling In European Life Sciences Sector
When the world was struggling with COVID-19 in 2020 and 2021, the partnership
between Indian and European organizations proved to be a historic accomplishment
in the field of global life sciences. It was able to deliver more than two billion doses
of the COVID-19 vaccine, which was developed by the University of Oxford and
AstraZeneca, both from the United Kingdom, and manufactured by Serum Institute
of India (SII) in India, to more than 170 countries starting in November 2020,
marking a significant milestone in the global pandemic response. India's economical
production in the biopharma industry allowed it to reach this significant milestone.
India's advantages, including cost-effective manufacturing, a skilled workforce, and
a growing but robust research ecosystem, are making it an attractive destination for
outsourcing and joint ventures. These collaborations have led to the development of
innovative healthcare solutions and have expanded market access for both Indian
and European firms. The India-Europe collaboration in life sciences has evolved into
a dynamic partnership fostering innovation, investment, and shared expertise. While
significant strides have been made in contract research, vaccine production, and
biosimilars, there remains potential for greater collaboration in new drug discovery
sciences. As European companies expand their R&D and manufacturing presence
in India, the mutual focus on academic research and healthcare resilience positions
this partnership as a global leader in life sciences innovation.

Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19-  induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in next generation therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.

BioPharma’s Transformative & Strategic  OUTLOOK 2025
The Indian biopharma industry witnessed notable transformative developments and
announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India’s strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry. Key developments in 2024 include an increase in
biosimilar approvals, enhanced collaborations for biologics and vaccines, and a focus on potential investments in cutting-edge technologies like Artificial Intelligence (AI), continuous manufacturing, and automation through biofoundries. Looking ahead, the industry is well-positioned to align with emerging trends that are shaping the global biopharma landscape for 2025 and beyond.These include the growing emphasis on precision medicine, a shift towards sustainablebiomanufacturing practices, and an increase in demand for advanced therapies such as cell
and gene therapies. With over $200 billion worth of biologic patents set to expire by 2030, Indiancompanies are poised to play a pivotal role in driving the next wave of innovation and accessibilityin biologics and biosimilars.

Will Boosting Biofoundries Transform India's Biomanufacturing Landscape?
Biofoundries hold the potential to emerge as the backbone of biomanufacturing 
and synthetic biology, offering integrated infrastructure to streamline the design, 
construction, and testing of genetically engineered organisms. Biofoundry is a place where biomanufacturing meets automation. The highly modular structure of a 
biofoundry helps accelerate the design-build-test-learn (DBTL) workflow to deliver 
products fast and in a streamlined fashion. Advanced platforms to enable rapid, 
high-throughput experimentation, and automating processes that were once labourintensive and time-consuming is a central theme. India has come up with multiple initiatives to support and set up biofoundries, including the BioE3 (Biotechnology for Economy, Environment and Employment) Policy, the Bio-RIDE scheme, and the Vigyan Dhara scheme. The BioE3 Policy lays out plans for accelerating the transition to biomanufacturing by promoting integrated use of Artificial Intelligence (AI), digitalisation with ‘omics’, and upstream biotechnology innovations through bio-AI hubs, biofoundries, and biomanufacturing hubs across the country. With the new BioE3 Policy in place, coming years will provide insight into how biofoundries will play a role in boosting innovation, scale-up and commercialisation of biobased products. In addition, with a Global Biofoundry Alliance now established to coordinate biofoundry activities and innovations worldwide, the question arises: how is India positioned in this rapidly evolving field, and what role do biofoundries play in India’s biomanufacturing initiatives? 

BHARAT EYES GLOBAL BIOMANUFACTURING DOMINANCE: Boosting Innovation, 
Collaboration & Entrepreneurship with BioE3 Policy Bharat has demonstrated a strong economic growth in the past decade and is poised to be amongst the global leaders in the next industrial revolution by leveraging emerging technologies 
and new innovative solutions. Bharat is competitively positioned to be amongst the global leaders in futuristic manufacturing that leverages living systems. Biomanufacturing can fundamentally transform the global economy from today’s consumptive manufacturing paradigm to the one based on regenerative principles. Biomanufacturing refers to the use of engineered microbial, plant, and animal (including human) cells with increasing precision and control to produce 
commercially important products on scale. These are versatile processes that have the potential to create bio-based products allowing efficient utilisation of resources, in a scalable and costeffective manner with reduced environmental impact. Keeping in view the national priority of steering Bharat on the path of accelerated ‘Green Growth’, an integrated BioE3 (Biotechnology for Economy, Environment and Employment) Policy for “Fostering High-Performance Biomanufacturing” with an aim to make a green, clean, prosperous, and self-reliant Bharat was released on September 12 at Global Bio-India (GBI) 2024. 

Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs). India is the source of around 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different APIs. However, India imports about 70 per cent of its APIs from China as it’s a cheaper option than manufacturing them domestically. There were 58 APIs in which India was heavily dependent on China. In the case of 45 APIs, India was dependent on China for 100 per cent of imports. Out of these 58 APIs, 29 APIs are manufactured through fermentation and 29 APIs are manufactured through chemical synthesis. The Department of Pharmaceuticals has drawn up a list of 56 APIs to prioritise them for the Make-in-India initiative. These include APIs or bulk drugs that go into the making of essential drugs, such as antibiotics, anti-HIV medicines, and the humble but indispensable paracetamol. The plan to make APIs in India has been in the works for some time but the Council of Scientific and Industrial Research (CSIR ) was engaged only recently. Let’s see how these steps taken by the government help to promote the production of KSMs and APIs in India in the coming years.

Why INDIA must turn BIOSIMILAR POWERHOUSE by 2030
Biosimilars could potentially enhance patient access to treatment of various malignant and nonmalignant conditions by reducing costs. Since the introduction of the first biosimilar in 2000 in India, a vaccine for hepatitis B, the development and utilisation of "biosimilars or similar biologics" have experienced significant growth. Each year, regulatory bodies are approving numerous similar biologics for the management of both cancerous and noncancerous illnesses. India has firmly positioned itself as a key player in the global production of similar biologics, benefiting from its large population. Despite the considerable potential and high expectations for India, there are substantial challenges that must be overcome to 
maintain this leadership position. To realise their full potential and sustain their global leadership, Indian biopharmaceutical companies must enhance their technological capabilities and enhance the skills of their workforce. This will require a supportive environment from both the government and regulatory agencies.

MediTech Stackathon 2024 to Drive Explosive Growth
India's medtech industry holds immense potential, with projections estimating a growth rate of 28 per cent annually, reaching a size of $50 billion by 2030. Currently, India is the fourth largest market for medical devices in Asia and among the top 20 globally. Net imports for 2022-23 stands at $4.101 billion with import coverage ratio of 0.45. The sector has witnessed a surge in imports, driven primarily by countries like the US, China, and Germany, however, India's robust policy ecosystem presents opportunities for exports and reducing import dependence through domestic manufacturing. Exports have overtaken imports in consumables and disposables during last year. The industry now needs to continue with the momentum in other pillars of the medtech sector. Against this backdrop of immense potential, the Department of Pharmaceuticals launched Meditech Stackathon 2024, which
seeks to harness the collective expertise of stakeholders to propel the industry towards unprecedented heights of innovation and self-reliance. With optimal support and participation from all stakeholders, initiatives like Meditech Stackathon will take the Indian medtech industry to the next levels to become self-reliant.

How Deep Tech is Powering India's Biopharma Future
Advancements in cutting-edge innovative  technologies and the increasing  availability of  data have enabled various domains of the biotech and pharma industries to leverage resourceful approaches in driving progress, maintaining 
competitive advantage and accomplishing the ultimate goal of improved patient outcomes. Deep tech ventures, also referred to as hard tech  as opposed to regular digital platforms, primarily focus on the fundamental core issues of a business. For India to become an ‘innovation hub’, with concerted transformative efforts of leaders 
and experts in life sciences, biotech, pharma, and healthcare, deep tech is pivotal. Experts opine that the next wave of startups from India, which is already gaining considerable traction, would be on  deep tech and IP-based devices. Let's take a closer  look at India’s deep tech startup landscape and the vision of a successful deep tech ecosystem.

India’s Life Science Instrumentation Industry: A Disruptor with Global Ambitions?
The Indian laboratory and analytical instrument industry is on the brink of a
transformative journey, propelled by rapid technological advancements and a growing emphasis on indigenous innovation. With the convergence of cutting-edge technologies such as Artificial Intelligence, Machine Learning, Big Data Analytics, Online and Atline testing, Cloud computing, and Process Analytical Technologies, the industry is poised for accelerated growth and expansion. Experts from different fields of the industry have highlighted the burgeoning opportunities for domestic players in the laboratory equipment and analytical instrument segment, exploring the evolving landscape, challenges, and strategies for fostering innovation and competitiveness.

Adopting ‘Green Approach’  in Drug Discovery
In the fast-changing global industrial arena, sustainability has become quite crucial. It is a critical issue across multiple  industries; the healthcare and clinical research sectors are no exception. Hospitals and clinical facilities produce tonnes of waste alongside carbon emissions. Medical research consumes non-renewable resources at a staggering rate, which can have a long-term impact on the environment. Sustainable drug discovery and development is positioned as a key initiative in the longdrawn fight against climate change and reducing the detrimental impact on the environment, linked with the health and clinical industry. Let’s explore how India can nail this ‘green target’.

What’s Shaking Up India’s Life Sciences Real Estate Sector?
India, in the last few decades, has witnessed the IT and manufacturing sectors invest heavily in real estate and infrastructure. However, in the post-pandemic era, we see life sciences companies require space to innovate, for R&D, and manufacture at scale. The demand for life sciences-related real estate has significantly increased. Both greenfield and brownfield projects have surged, as the pandemic fuelled the demand for locally manufactured pharma and medical products. This story attempts to encapsulate the changing facets of the life sciences real estate market in India, where the country is remarkably progressing in innovation and R&D, which in turn are fuelling the demand for specialised facilities, biotech/MedTech parks, research hubs with modern amenities and collaborative multidisciplinary ecosystems under one roof.

Can organoids usher in cheap & effective cancer therapeutics?
Dozens of science and technology development payloads returned to Earth from the International Space Station (ISS) as SpaceX’s 29th Commercial Resupply Services
(CRS) mission, contracted by NASA, successfully concluded on December 22, 2023. More than 30 payloads sponsored by the ISS National Laboratory returned on this mission, many of which were life science investigations aimed at benefiting
humanity by improving care for patients on Earth. One among the payloads was an investigation from the University of California, San Diego (UCSD), which studied microgravity’s effects on stem-cell derived brain organoids (lab grown replicas of human organs). While this might seem like science fiction, the story of organoids dates back to 1907. Fast forward to today, these tiny replicas of human organs are experiencing a dramatic surge in popularity, transforming the face of drug discovery research. Dubbed as powerful ‘human modelling systems’, organoids are paving the way for personalised medicines and shaking up the global drug development scene.
India, too, is joining the bandwagon. Let’s explore the world of organoids and how it is pushing the boundaries of personalised medicine research and precision oncology.

Can Biotech Industry Hit $150B by Leveraging Technology, Innovation & Startups?
The biotechnology industry is currently navigating a complex landscape. While revenues have normalised after the COVID’s surge, the looming patent cliff and increased regulatory pressures pose significant challenges. Despite these obstacles, the industry’s long-term potential remains strong, fuelled by a robust innovation pipeline and opportunities for operational efficiency. Biotech companies, according to a report by NoyMed CRO, can secure future growth and address market challenges by focusing on capital allocation, establishing beneficial partnerships, and leveraging technology. Though the path forward is complex, the future of the biotechnology industry remains bright in 2024 as India has set target of reaching $150 billion by 2025 due to its inherent strengths and dedication to innovation.

From Exponential Growth to PHARMA BOOM
The Indian pharmaceutical industry is experiencing a dynamic growth landscape, marked by strategic initiatives such as partnerships, investments, Memoranda of
Understanding (MoUs), and collaborations. Despite geopolitical uncertainties like
the Israel-Palestine and Russia-Ukraine conflicts lingering in 2023, the healthcare
and pharma sector in India continues to gain momentum through new investments
and collaborative efforts. Major global players are actively engaging in partnerships, MoUs, and collaborations to secure a substantial global market share.
In 2023 alone, more than 30 partnerships, MoUs and other collaborations have been
forged to boost India’s pharmaceutical growth trajectory. The Indian pharmaceutical products market is projected to hit $130 billion by the end of 2030.

AI-Driven Therapeutics for DIABETES
Diabetes mellitus, a chronic metabolic non-communicable disease (NCD), has attained epidemic proportions worldwide. Several studies conducted over the last two decades have revealed a huge burden of diabetes in India, which translates to a large population of individuals at risk of not only cardiovascular disease but also chronic complications of diabetes such as kidney, foot, and eye disease. The cost of 
treating them is crippling not just individuals, but also the society and the country as a whole. For instance, diabetic foot ulcers and infections are responsible for more than 30 per cent of hospitalisations related to diabetes mellitus. On the other hand, there is a higher prevalence of diabetic retinopathy among the urban population than in the rural population. India must step up state-specific policies and technological interventions on a war footing to arrest the rapidly rising epidemic of diabetes.

Transforming Healthcare With Generative AI
Generative AI is making a significant impact in the fields of life sciences and healthcare, transforming the way research, diagnosis, and treatments  are  conducted. By leveraging the power of Generative models, researchers are now exploring ways to generate synthetic data, simulate biological processes, optimize treatment strategies, and facilitate the development of novel therapeutics. This technology is the latest trend that has got global and India’s C-Suite health science professionals explore its implications to develop indigenous solutions. This story, therefore, explores how Generative AI is selling itself to emerge as the new frontier 
in the horizon for the booming healthcare industry. Highlighting some of the significant developments in this technology space, this article also has a few Indian leaders voicing their opinions on exploring Generative AI to progress their businesses and services.

Will 3D Bioprinting Turn Disruptor in Healthcare? 
3D bioprinting has come to the limelight recently and a lot of research activities have been undertaken for the same. Creating organ models that can be used for preclinical testing of drugs and other interventional molecules and creating organ scaffolds for clinical transplantation can become a breakthrough in the healthcare domain. Though the technology is yet to be accepted fully among India’s medical sector, current efforts by academics and research labs will ensure that 3D bioprinting provides personalised solutions for individual patients.

Rise of HEALTHCARE WEARABLES
Wearable technology is becoming increasingly popular in the healthcare industry.
These devices can track a variety of health metrics, including heart rate, blood pressure and sleep patterns. They can also be used to provide remote patient monitoring and early warning systems. The wearable healthcare market in India is rapidly growing due to the increasing awareness of health and fitness among the Indian population, the prevalence of chronic diseases and the government’s support for the adoption of wearables. Of course, there are a few challenges that need to be addressed, such as the lack of regulatory guidelines for wearables, the high cost of some devices and the lack of awareness about the benefits of wearables among the general public. Despite these challenges, the wearable healthcare market in India is expected to continue to grow in the coming years. This growth will be driven by the increasing demand for wearables from consumers and healthcare providers. Let’s explore further.

The verdict is out. And the result has drawn applause – for the industry captains who are winners of the Indian Bio & Health Sciences Industry awards and also for the Jury members who managed this tough task in a two-hour-long deliberation. Since its institution in 2003, the BioSpectrum Excellence Awards honour the achievements of the Indian Bio & Health Sciences Industry leaders. The Annual Gala Awards Nite on June 30, 2023, where these were given away, has been the most eagerly awaited event in the industry.

Can India Create 50K BIOTECH STARTUPS?
2021 was a landmark year for the startup ecosystem when for the first time biotech industry in India recorded over 1000 new startup registrations in a single year, as per the Bioeconomy Report 2022. Dr Jitendra Singh, Union Minister of Science & Technology, Government of India, has revealed that the number of Biotech startups in the country has increased from 50 to over 5,000 in the last 8 years, because of the support and enabling environment provided by Prime Minister Narendra Modi since
2014. It is expected to cross the figure of 10,000 by 2025, he said.

Could 7.5% R&D Spends Make India PHARMA INNOVATION HUB?
Areport by India Brand Equity Foundation (IBEF) stated that India’s domestic pharmaceutical market was estimated at $42 billion in 2021, which is likely to reach $ 65 billion by 2024 and may further expand to reach nearly $120-130 billion by 2030. The country’s vast pool of scientific talent, strong system of higher education, low operating costs, conducive regulatory environment and supportive government
policies have made it an attractive destination for drug development, clinical trials, and commercial manufacturing. A growing population, significant R&D investments, a modernised manufacturing base and the prevalence of chronic diseases have fuelled the growth of the pharma sector. And the backbone of the success can be largely attributed to robust R&D measures in recent years. Post COVID-19, pharma players have increased their R&D investment.

BIOTECH INDUSTRY LEADERS 2021-22
Serum Institute of India continues to lead the Indian Biopharmaceutical Industry Survey 2022 . BioSpectrum India brings to you the survey results of the Biotechnology Industry, across verticals such as biopharma, bioservices, industrial enzymes, medical devices and diagnostic sectors, for FY 21-22. Read more to find out the winners of our biotech industry survey 2022.

India’s vaccine SUPREMACY
India has been able to mark its presence in both the human and livestock vaccine domain, thanks to rigorous research undertaken by government institutes and private vaccine manufacturers. Vaccines made by Indian companies have taken the country to newer heights and were lauded by the rest of the world as well, during the pandemic for India’s capacity to deliver vaccines to many nations in urgent need of jabs. We take a historical glance at India’s steady growth and prowess in the vaccine manufacture and research sphere since the 19th century, catering to inoculations for humans and livestock alike.

Leveraging  Early Cancer Detection Tech
Cancer is fast turning into an ‘epidemic’ and is the second leading cause of death 
globally. As per the Globocan Report of 2020, the annual global burden of cancer 
in 2020 in the country had hit the 1.93 crore mark with an annual death of 1 crore. 
The projected annual new cases globally will be 2.84 crore in 2040. According to 
the same report, the number of new cancer cases in India will be a whopping 17 
lakh annually by 2035. In light of such alarming numbers, early detection still holds 
the key to cancer prevention. Though several technologies have been launched that 
can provide solace to the medical fraternity and patients alike in early detection, 
awareness on the disease and pre-testing remains a challenge in India. There are 
a few ‘Breakthrough Tech’ that hold a lot of promise. For instance, the Imperial 
College London has recently developed a surgical knife capable of identifying 
tumours that can detect endometrial cancer within seconds. The surgical knife 
could aid the treatment strategies for cancer by enhancing the diagnosis time and 
giving the go-ahead for treatment. Let’s explore some notable new technologies 
and also try to uncover the challenges in the fight against cancer.

How genomics Can REVOLUTIONISE HEALTHCARE
A genomic revolution is taking place in India, where the value of genomic tests is being recognised in the prevention and diagnosis of diabetes, cardiovascular, cancer, carrier status, among others. Having the power to identify accurate preventive solutions to chart out treatment options for patients, predictive genomic testing is seen as the next major weapon in the arsenal of cutting-edge healthcare tech that can improve patient outcomes without relying on a curative approach. Let’s learn more from industry leaders and experts in the field of leveraging genomics.

Can INDIA Dethrone CHINA In API PRODUCTION?
The past decade has witnessed a steady growth and commitment of the Indian government in addressing issues like ‘self-reliance and self-sufficiency’ in all aspects of governance and decisions. While sops and subsidies were, indeed, crucial to many concerns of industries and stakeholders, key decisions and schemes were lacking, until numerous ‘Aatmanirbhar Projects’ were kicked off by the Centre. One such crucial initiative addresses the need for Bulk Drugs Parks in India, making the country less dependent on Chinese Active Pharmaceutical Ingredients (APIs), providing more employment and generating more revenue that will add to the country’s GDP. A laudable step has been taken with the launching of three Bulk Drugs projects across three states in the country, with an estimated time of completion set at 5 years. We shall take a closer look at what the project entails and seek expert views from a few industry stalwarts.

Bio Spectrum Magazine Cover - BioSpectrum India  May 2025 Edition

BioSpectrum India  May 2025

Bio Spectrum Magazine - BioSpectrum India  May 2025

Bio Spectrum Magazine Cover - BioSpectrum India April  2025 Edition

BioSpectrum India April  2025

Bio Spectrum Magazine - BioSpectrum India April  2025

Bio Spectrum Magazine Cover - March 2025 Edition

March 2025

Bio Spectrum Magazine - March 2025

Bio Spectrum Magazine Cover - February 2025 Edition

February 2025

Bio Spectrum Magazine - February 2025

Bio Spectrum Magazine Cover - BioSpectrum India Jan 2025 Edition

BioSpectrum India Jan 2025

Bio Spectrum Magazine - BioSpectrum India Jan 2025

Bio Spectrum Magazine Cover - BioSpectrum India Dec  2024 Edition

BioSpectrum India Dec  2024

Bio Spectrum Magazine - BioSpectrum India Dec  2024

Bio Spectrum Magazine Cover - BioSpectrum India  Nov 2024 Edition

BioSpectrum India  Nov 2024

Bio Spectrum Magazine - BioSpectrum India  Nov 2024

Bio Spectrum Magazine Cover - BioSpectrum India Oct 2024 Edition

BioSpectrum India Oct 2024

Bio Spectrum Magazine - BioSpectrum India Oct 2024

Bio Spectrum Magazine Cover - September 2024 Edition

September 2024

Bio Spectrum Magazine - September 2024

Bio Spectrum Magazine Cover - August  2024 Edition

August  2024

Bio Spectrum Magazine - August  2024

Bio Spectrum Magazine Cover - July 2024 Edition

July 2024

Bio Spectrum Magazine - July 2024

Bio Spectrum Magazine Cover - June 2024 Edition

June 2024

Bio Spectrum Magazine - June 2024

Bio Spectrum Magazine Cover - May 2024 Edition

May 2024

Bio Spectrum Magazine - May 2024

Bio Spectrum Magazine Cover - April 2024 Edition

April 2024

Bio Spectrum Magazine - April 2024

Bio Spectrum Magazine Cover - March 2024 Edition

March 2024

Bio Spectrum Magazine - March 2024

Bio Spectrum Magazine Cover - February 2024 Edition

February 2024

Bio Spectrum Magazine - February 2024

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.

March 2013

1. You agree that the use of Magzter.com, the application and its services, are at solely at your own risk. Neither Magzter.com nor its associates nor employees nor third party content providers guarantee that the service will be completely uninterrupted or error-free or foolproof against miscreant activities. Nor do they warranty that you will get the exact results as expected or promised by the website or product.

11. THE SERVICE AND ALL PUBLICATIONS ARE PROVIDED ON AN 'AS IS' AND 'AS AVAILABLE' BASIS. MAGZTER, ITS AFFILIATES, SUPPLIERS, LICENSORS AND AGENTS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, NEITHER MAGZTER NOR ITS AFFILIATES, SUPPLIERS, LICENSORS OR AGENTS, MAKES ANY WARRANTY THAT (I) THE SERVICE WILL MEET YOUR REQUIREMENTS, (II) THE SERVICE WILL BE UNINTERRUPTED, TIMELY, SECURE, OR ERROR-FREE, (III) THE INFORMATION THAT MAY BE OBTAINED FROM THE USE OF THE SERVICE OR THAT MAY BE CONTAINED IN THE PUBLICATIONS WILL BE ACCURATE OR RELIABLE, OR (IV) THE QUALITY OF ANY PUBLICATIONS OR THE SERVICE WILL MEET YOUR EXPECTATIONS. YOU ARE SOLELY RESPONSIBLE FOR OBTAINING AND MAINTAINING RELIABLE INTERNET CONNECTIVITY AND YOUR DEVICE. MAGZTER IS NOT RESPONSIBLE FOR YOUR INABILITY TO DOWNLOAD CONTENT. ANY MATERIAL DOWNLOADED OR OTHERWISE OBTAINED THROUGH THE USE OF THE SERVICE IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER SYSTEM OR MOBILE DEVICE OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY SUCH MATERIAL. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM MAGZTER OR THROUGH OR FROM THE SERVICE SHALL CREATE ANY WARRANTY.

2. You will maintain and promptly update that information to keep it true, accurate, current and complete. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer, and you agree to accept responsibility for all activities that occur under your account, including the selection and use of all content and services.

2.You will maintain and promptly update that information to keep it true, accurate, current and complete. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer, and you agree to accept responsibility for all activities that occur under your account, including the selection and use of all content and services.

3. In no event will Magzter.com or any person or entity or third party involved in the creation, production and distribution of the content on the website and the application be liable in contract or legally for any damages, including and not limited to, direct, indirect, incidental, special, and consequential incurred to you while or on using Magzter.com. By registering on the website or downloading the application, you agree that the provisions mentioned in this section shall apply to all use of and content on the website and the application.

3. Without prior written or authorised permission from Magzter, you should not modify, copy, distribute or sell any content obtained from Magzter as everything published here is the proprietary property of Magzter or its licensors. As such unauthorised use may also violate applicable laws including copyright and trademark laws, Magzter strictly prohibits these and will terminate your access and account if any such illegal activity is proved or detected. You should also stand liable for the damages caused by these unauthorised activities. Except as permitted by the Publication's lawful owner, you acknowledge that you do not acquire any ownership rights by downloading Publications accessed through the Service. Except as explicitly required under copyright law or permitted by the features of the Service you may not modify, reverse engineer, publish, transmit, display, participate in the transfer or sale, create derivative works of, or in any way commercially exploit or provide to a third party the content of the App, the Publications, or any portion of them without the express permission of Magzter and the owner of such content. We do not grant you any licenses, express or implied, to the intellectual property of Magzter or Magzter's licensors.

5. You specifically acknowledge that Magzter.com is not liable for any kind of defamatory or offensive or illegal conduct of other users or third parties or their content and that the risk of injury from the foregoing rests entirely with you.

8. Magzter reserves all rights to monitor the content published and inputted by you for the purpose of determining whether you are compliant with these terms and conditions and other operating rules determined by Magzter. Magzter has the right to take decisions about the content and delete them at its own will.

9. Magzter is a distributor and NOT a publisher of the Publications and so Magzter has no editorial control over the content, including opinions, advice, statements, services, offers etc., that is represented in the magazines. So Magzter will not take responsibility for the accuracy or the reliability for any information or facts provided therein or that is made available through the service, by anyone other than authorised Magzter employees who are acting on their official capacities. Accordingly, we have no editorial control over the Publications. Any opinions, advice, statements, services, offers or other information or content expressed or made available by third parties, including those made in Publications offered by the Service, are those of the respective author(s) or publisher(s) and not of Magzter. Magzter will not be liable for any loss or damage caused by your reliance on information obtained through the Service or from the Publications. The Service may contain links to other Internet sites and third-party resources and Magzter does not assume any responsibility or liability for communications or materials available at such linked sites. These links are provided for your convenience only. You are solely responsible for understanding any terms and conditions that may apply when you visit or place an order through a third-party site.

Choose your favorite titles from 40+ exciting categories

Details of the objectionable content, including its link on our platform

Download your favorite titles and read them offline, anytime and anywhere

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines and newspapers from thousands of best-selling titles.

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from thousands of best-selling titles.

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from {{magCount}} best-selling international titles.

Girish Ramdas is the Co-founder and CEO of Magzter, a New York based startup that has been making waves in the global digital publishing business. Magzter has crossed 80 million users since its inception in 2011 from more than 150+ countries with 1000s of magazines, newspapers and books from more than 4,500 publishers worldwide. He has more than 25 years of experience in cross-platform publishing, including print, mobile, and Web development. During this period, he has co-founded and run three successful start-up businesses. He has enabled magazine companies to go digital and helps them monetize their content across the digital world. Girish's deep industry experience in online, mobile and publishing ecosystems has made him an expert in acquisition, marketing and monetizing digital content across platforms globally.

In the event that you encounter any objectionable content on our platform, we have put in place a grievance redressal policy to address your concerns.

Magzter Inc. (“Company”, “we”, “us” or “our”) knows that you care about how your personal information is used and shared. Please read the following privacy policy (the “Policy”) to learn more about our privacy practices. By visiting any of the websites operated by the Company, and any sub-domains thereof, or using any of our mobile applications and other methods of content distribution (collectively, the “Service”), you acknowledge that you accept the practices and policies outlined in this Policy, and you hereby consent that we will collect, use, and share your information in the following ways.

Magzter Inc. is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 80 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

Magzter is committed to providing a safe and secure platform for our users. Please note that Magzter is merely a platform for publishers to distribute their content. We do not control or endorse the content published on our platform. We cannot be held responsible for the actions of our publishers or their content.

Magzter is not responsible for compensating any party that has suffered damages or incurred costs due to any content, or part of the content, that violates their rights. Magzter is not liable to face any legal action in civil court for any violation of rights caused by any content, or part of the content, that infringes the rights of a third party.

Magzter offers the world’s largest {{allyoucanread}} subscription service called {{gold}} which gives digital readers unlimited access to 9,000+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

Magzter offers the world’s largest “All-You-Can-Read” subscription service called Magzter GOLD which gives digital readers unlimited access to 9,000+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

Name

Note: This will only share the cover and the publication information, but not the content.

Please fill out this form if you need any help regarding publishing your content on Magzter

Prior to Magzter, he was the President of Dot Com Infoway (DCI) and Galatta Media. His duties included strategic marketing, partnership development, and monetizing content globally. DCI grew from a small team of 3 in 2000 to 300 by 2011 and was dealing with web, software and app development for clients globally.

Since we launched, Magzter has been committed to partnering with global organizations to provide the greatest possible newsstand technology & service to our customers. Whether you are looking to offer magazine subscriptions to your customer database or just want to learn more, Magzter is committed to helping your business grow. To find out more, please fill out the questionnaire below:

The DMCA allows us to restore the removed content if the party filing the original DMCA Notice does not file a court action against you within ten business days of receiving the copy of your Counter Notice.

This Policy covers Company’s treatment of personally identifiable information (“Personal Information”) and other information about you and your computer or device that Company gathers when you are accessing the Service. We may collect Personal Information from you, as explained in more detail below, and we use this Personal Information internally in connection with our Services, including to personalize, provide, and improve our products, services, content, and advertising, and to allow you to set up a user account and profile, to contact you, to fulfill your requests for certain products and services, and to analyze how you use the Services. In certain cases, we may also share some Personal Information with third parties, but only as described in point 4.

This title is included with your Magzter GOLD subscription

To analyze the quality of content and provide appropriate feedback to publishers

We have designated a Grievance Officer to address any complaints related to objectionable content.

We request that any complaint related to objectionable content be sent to the Grievance Officer through email to the above-mentioned email address. We also request that you provide the following details when making a complaint:

and the App that provides you the capability to order, subscribe to and receive the delivery of various magazines, books, news and magazine and publication related content (collectively known as 'Publications') and to have these digital versions of the Publications delivered to you

c. We also collect information associated with your use of the application in order to make personalized recommendations. If you provide your third-party account credentials to us, you understand some content and/or information in those accounts (“Third Party Account Information”) may be transmitted into your account with us if you authorize such transmissions, and that Third Party Account Information transmitted to the Service is covered by this Policy.

f. The Personal Information we collect allows us to respond to your requests, improve our products and services, customize the advertising and content you see, and communicate with you about new products.

is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 88 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

n. We will also use usage information in order to ensure users adhere to our Terms of Use. For example, a user’s usage information will help us confirm that a user only downloads a magazine or other content a permitted number of times or to a permitted number of devices.

which gives digital readers unlimited access to 9,000+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

{{magzter}} is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 88 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

Bio Spectrum Magazine - June 2016

Bio Spectrum Magazine - June 2016

In this issue

Bio Spectrum Magazine Description: